BPC-157 10mg

About BPC-157 10mg

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein naturally present in human gastric juice. First characterised by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, BPC-157 has since become one of the most widely studied peptides in preclinical research, spanning gastrointestinal biology, musculoskeletal repair, neuroprotection, and cytoprotective signalling.

What makes BPC-157 particularly unusual among bioactive peptides is its stability in gastric juice. Most peptides degrade rapidly in the acidic, enzyme-rich environment of the stomach, but BPC-157 demonstrates remarkable resistance to enzymatic breakdown — a property consistent with its origin as a fragment of a naturally occurring gastric protein. This stability has practical implications for research design, as it opens the door to oral administration routes in experimental models where most peptides would require injection.

Mechanistically, BPC-157 does not operate through a single defined receptor. Instead, research points to activity across multiple interconnected systems, including modulation of the nitric oxide (NO) system, upregulation of growth factor expression (notably VEGF, EGF, and FGF pathways), promotion of angiogenesis, and activation of the FAK-paxillin signalling pathway involved in cell migration and tissue organisation. This multi-pathway profile partly explains the breadth of biological effects observed across diverse preclinical models.

Research Summary

The gastrointestinal tract has been the most thoroughly investigated context for BPC-157 research, which is fitting given the peptide’s gastric origins. Sikiric et al. have published extensively on BPC-157’s effects in rodent models of gastric ulceration, demonstrating accelerated healing of cysteamine-induced duodenal ulcers with clear dose-dependent responses. Protective effects have also been observed in models of NSAID-induced gastrointestinal damage, ethanol-induced gastric lesions, and stress-induced ulceration. In inflammatory bowel disease models, BPC-157 reduced the severity of experimentally induced colitis in rats when administered either intraperitoneally or intraluminally, suggesting activity through both systemic and local routes (Sikiric et al., 1993; Sikiric et al., 2003; Sikiric et al., 2006). More recent work from the Zagreb group has explored BPC-157 in the context of the gut-brain axis, investigating how its gastrointestinal effects may relate to broader systemic and neurological outcomes — a line of inquiry that reflects growing scientific interest in enteric-central nervous system communication.

Tendon and ligament repair represents one of the most compelling areas of BPC-157 research. Staresinic et al. (2003) demonstrated that BPC-157 administration accelerated healing of transected Achilles tendons in rats, with treated groups showing improved biomechanical properties and enhanced histological organisation compared with controls. The peptide appeared to promote tendon fibroblast proliferation and accelerate the transition through the organisational phase of healing. Cerovecki et al. extended this work to models of medial collateral ligament injury, reporting similar improvements in structural repair and functional outcomes. Chang et al. (2011) provided further mechanistic insight by demonstrating that BPC-157 promoted tendon-to-bone healing in a rat rotator cuff model through activation of the FAK-paxillin pathway, with treated groups exhibiting increased collagen fibre organisation and improved load-to-failure measurements.

BPC-157’s effects on angiogenesis — the formation of new blood vessels — have been consistently documented across multiple experimental systems. Studies using the chicken chorioallantoic membrane (CAM) assay and various rodent wound models have shown enhanced blood vessel formation in BPC-157-treated groups. This pro-angiogenic activity, mediated at least in part through upregulation of VEGF receptor expression, is considered a key contributor to the accelerated tissue repair seen across different injury models. Seiwerth et al. (2018) provided a comprehensive review of this angiogenic profile, linking it to the peptide’s broader growth factor modulation effects.

Neuroprotective research has expanded considerably in recent years. In rodent models, BPC-157 has been studied in the context of traumatic brain injury, peripheral nerve transection, and spinal cord injury, with findings including reduced lesion size, improved functional recovery scores, and enhanced nerve regeneration (Tudor et al., 2010; Perovic et al., 2019). The peptide has also demonstrated interactions with the dopaminergic and serotonergic systems, with studies showing that BPC-157 can modulate the effects of dopamine-related agents in animal models and counteract some behavioural and neurochemical consequences of both dopamine agonists and antagonists (Sikiric et al., 2010). These findings have prompted interest in BPC-157’s potential relevance to research on neurotransmitter dysregulation, though this work remains at an early preclinical stage.

The cytoprotective properties of BPC-157 form a unifying thread across much of the published literature. The peptide has shown protective effects against a wide range of experimentally induced tissue injuries, including those caused by toxic agents, ischaemia-reperfusion protocols, and surgical trauma. Sikiric et al. (2014, 2018) have proposed that BPC-157’s interaction with the nitric oxide system — which appears to be bidirectional, counteracting both NO deficiency and NO excess depending on the experimental context — may serve as a central organising mechanism for many of these cytoprotective observations. This context-dependent modulation of NO pathways remains one of the more distinctive and widely discussed aspects of BPC-157 pharmacology.

Current research continues to build on these established foundations while exploring new territory. The breadth of BPC-157’s preclinical profile — spanning gastrointestinal protection, musculoskeletal repair, angiogenesis, neuroprotection, and cytoprotection — has sustained interest from research groups investigating tissue repair mechanisms and regenerative biology. While the majority of published data originates from the Sikiric laboratory in Zagreb, independent groups have increasingly contributed to the literature, and the peptide remains a subject of active investigation across multiple areas of preclinical science.